AgingResearch.NewsJoin free

Sermorelin

Sermorelin has been studied in 357 papers since 1984: 121 trials and 32 observational studies in people, 103 in animals, 78 in cells, 4 reviews; 2 in the past year. It is an approved medicine.

InterventionApproved 1990

357 papers study it5 findingsUpdated

More peptides

1 of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Against: findings that point the other way from most findings on the same outcome.

  • 1 lab
  • 1 finding against
  • Human trial8
  • Animals3

What did studies of Sermorelin find?

4

Studies of Sermorelin measured 4 outcomes; the most studied are high-affinity pituitary GHRH receptor-binding sites (1 study), pituitary GHRH receptor-binding affinity (1) and growth rate (1).

High-affinity pituitary GHRH receptor-binding sites

downin rats1upin rats1

1 study

  1. Sermorelin decreases high-affinity pituitary GHRH receptor-binding sites in rats (2.4-fold decrease versus 0.5 mg/kg BW; P < 0.05).

    “Treatment with 1.0 mg/kg GHRH decreased the number of high affinity pituitary GHRH-R-binding sites by 2.4-fold compared with that in rats treated with 0.5 mg/kg BW”

    Animalscompared with 0.5 mg/kg BWhuman GHRH-(1-29)NH2pituitary1.0 mg/kg BW daily14 daysmales

    Differential in vivo regulation of the pituitary growth hormone-releasing hormone (GHRH) receptor by GHRH in young and aged rats

    Endocrinology

  2. Sermorelin increases high-affinity pituitary GHRH receptor-binding sites in rats (2-fold).

    “treatment with 0.5 mg/kg GHRH increased the number of high affinity pituitary GHRH-R-binding sites by 2-fold (P < 0.05)”

    Animalshuman GHRH-(1-29)NH2pituitary0.5 mg/kg BW daily14 daysmales

    Differential in vivo regulation of the pituitary growth hormone-releasing hormone (GHRH) receptor by GHRH in young and aged rats

    Endocrinology

More on High-affinity pituitary GHRH receptor-binding sites

Pituitary GHRH receptor-binding affinity

upin rats1

1 study

  1. Sermorelin improves pituitary GHRH receptor-binding affinity in rats.

    “treatment with 1.0 mg/kg GHRH restored the affinities of high and low affinity classes of GHRH-binding sites”

    Animalsrestoration toward values in 2-month-old ratshuman GHRH-(1-29)NH2pituitary1.0 mg/kg BW daily14 daysmales

    Differential in vivo regulation of the pituitary growth hormone-releasing hormone (GHRH) receptor by GHRH in young and aged rats

    Endocrinology

More on Pituitary GHRH receptor-binding affinity

Growth rate

downin rats1

1 study

  1. Sermorelin decreases growth rate in rats (-17%; P < 0.05).

    “slowed the growth rate by 17% (P < 0.05)”

    Animalshuman GHRH-(1-29)NH21.0 mg/kg BW daily14 daysmales

    Differential in vivo regulation of the pituitary growth hormone-releasing hormone (GHRH) receptor by GHRH in young and aged rats

    Endocrinology

Somatostatin

upin rats1

1 study

  1. Sermorelin increases somatostatin in rats (+45% at both doses; P < 0.05).

    “increased hypothalamic SRIF content by 45% (P < 0.05)”

    Animalshuman GHRH-(1-29)NH2hypothalamus0.5 or 1.0 mg/kg BW daily14 daysmales

    Differential in vivo regulation of the pituitary growth hormone-releasing hormone (GHRH) receptor by GHRH in young and aged rats

    Endocrinology

More on Somatostatin

Has Sermorelin been tested in people?

Yes: 121 trials and 32 observational studies in people have been published.

Approved

Latest